Ç elik et al 1 reported higher levels of endothelial cell-specific molecule 1 (endocan) in patients with essential hypertension (EH) compared to controls. They also demonstrated a positive correlation of serum endocan level with serum triglyceride, hemoglobin, white blood cell (WBC) count, and platelet counts within the EH group. However, there was no significant correlation of serum endocan level either with aortic strain, aortic stiffness (b) index, and aortic distensibility or the other echocardiographic and demographic parameters within the EH group. 1 Endocan is a vasculoprotective molecule in normal physiological conditions; it protects the endothelium from migration and proliferation of inflammatory cells. 2 However, if the endothelium is inflamed, the secretion of endocan into the bloodstream is significantly enhanced. 3 Essential hypertension causes impaired arterial elasticity regardless of the age of patients. 4 Inflammation and oxidative stress play a role in the development and progression of EH and aortic stiffness. 4, 5 All biomarkers involved in common pro-inflammatory and prooxidant pathways may be increased and/or have a diagnostic and prognostic role in EH and aortic stiffness. 5, 6 All biomarker studies in patients with EH and aortic stiffness should focus on which biomarker predicts the disease with high sensitivity and specificity.
In a previous study, Celik et al 7 demonstrated that young prehypertensive patients have increased markers of inflammation including high-sensitivity C-reactive protein (hsCRP) and WBC count compared to the controls. More importantly, impaired arterial stiffness is significantly associated with the markers of inflammation in patients with prehypertension. 7 However, one of the fundamental limitations of the present study is that the most reliable indicators of inflammation such as CRP or hsCRP values of the study population were not analyzed. Furthermore, the correlation between endocan and CRP or hsCRP was not investigated.
Recently, the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and monocyte to high-density lipoprotein cholesterol (MHR) have also been used as inflammatory biomarkers and have been shown to be independent risk factors for aortic stiffness, atherosclerosis, and cardiovascular events. [6] [7] [8] [9] [10] [11] In the study by Ç elik et al, 1 it was clear that the patients in the EH group had higher WBC and platelet counts as well as endocan compared to the control group. However, the study did not mention the combinations of these inflammatory biomarkers including NLR, PLR, and MHR. Besides, they did not analyze these possible confounding factors in the univariate and multivariate logistic regression model.
In conclusion, serum endocan as a novel indicator of systemic inflammation may have a predictive role in both EH and aortic stiffness. However, it cannot be concluded from the Ç elik et al 1 study that endocan is a surrogate marker of escalating aortic stiffness in patients with newly diagnosed EH.
